XTalks

SEPTEMBER 30, 2020

The two studies were recently published online in the journal Science, both of which were led by Jean-Laurent Casanova, an infectious disease geneticist at Rockefeller University. Upon encountering a virally-infected cell, interferons trigger an immediate local response, causing infected cells to produce proteins that fight the virus.

Antibody 135

Antibody Genetics Research In-Vitro 135

Drug Discovery World

MAY 13, 2024

MA: Regarding vaccine development specifically, and the role my team plays in the development of cryogenic electron microscopy (cryo-EM) technology, we see the study and dissemination of virus structures, and the proteins that comprise them, as vital to vaccine design. RA: How reliable are vaccines now for respiratory viruses such as flu?

Vaccination 59

Vaccination Vaccine Protein Antibody 59

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 1.351 variant.

Protein 97

Protein Vaccination Vaccine Trials 97

Drug Discovery World

APRIL 3, 2023

I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. What advantages do they offer over antibodies?   DS: How are aptamers currently used in the development of precision treatments?

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

XTalks

JULY 25, 2022

Epidermal growth factor receptor 2 (HER2)-positive breast cancer is one such type in which there is an overexpression of the HER2 protein. Later lines of treatment can include monoclonal antibodies, tyrosine kinase inhibitors and antibody-drug conjugates (ADCs). Vic-]Trastuzumab Duocarmazine Mechanism of Action.

Antibody 59

Antibody Drugs Clinical Trials Clinical Trials 59

XTalks

JUNE 18, 2021

This is why Regeneron’s announcement of positive clinical trial results that show its antibody cocktail treatment can cut deaths among hospitalized patients is welcome news. It is the first trial to demonstrate that any antibody treatment could improve survival in patients hospitalized with COVID-19. Regeneron Pharmaceuticals Inc.’s

Antibody 75

Antibody Immune Response Trials Clinical Trials 75

Pharma in Brief

DECEMBER 17, 2023

On December 4, 2023, the Federal Court held that a patent claiming a formulation of adalimumab, a monoclonal antibody used to treat autoimmune diseases, is valid and is being infringed by a biosimilar product. The Court found that this publication disclosed adalimumab and self-buffering protein formulations.

Antibody 52

Antibody Production Regulation Marketing 52

The Pharma Data

SEPTEMBER 4, 2020

The technique has been used to generate a high-affinity antibody against Arginase 2, an enzyme implicated in major human diseases. Therefore, the enzyme is a target for inhibitory therapeutic antibodies that could help restore immune function against cancer cells, the researchers note.

Antibody 52

Antibody Research Life Science Production 52

XTalks

JUNE 23, 2021

The team also talked about Regeneron’s monoclonal antibody treatment for COVID-19 that has been shown to reduce the risk of deaths by 20 percent among hospitalized COVID-19 patients in recent results from the UK RECOVERY trial. The treatment consists of two monoclonal antibodies that target the spike protein of SARS-CoV-2.

Antibody 52

Antibody Life Science Protein Vaccination 52

Pharmaceutical Technology

APRIL 18, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Protein 147

Protein Vaccination Vaccine Production 147

XTalks

AUGUST 8, 2022

Medicxi is a prominent international life sciences investment firm that invested in over 60 portfolio companies such as Versanis Bio, Rivus Pharmaceuticals, Capella Bioscience and more. One of Medicxi’s portfolio companies called MiroBio is set to be acquired by Gilead Sciences for approximately $405 million in cash.

Immune Response 98

Immune Response Antibody Life Science Engineer 98

Drug Discovery World

MAY 25, 2023

Several new products for the life sciences sector have been launched over the last month, from miniature semiconductor chip (MSC) technology to a new inhalation testing service. DDW provides an update.

Production 52

Production Reagent DNA Drugs 52

Drug Discovery World

OCTOBER 20, 2023

The latest acquisitions and strategic partnerships in the drug discovery and development sector reveal the areas where companies predict significant growth in the near future: proteomics, CAR-T, antibody discovery, artificial intelligence (AI) and microbiomics. We aim to continue to ‘open up’ the druggable antibody space.”

Drugs 52

Drugs Antibody DNA Gene Therapy 52

XTalks

JANUARY 6, 2021

Researchers at the National Institutes of Health (NIH) in the US have isolated small antibodies called “nanobodies” from a llama named Cormac that can block the SARS-CoV-2 coronavirus. Nanobodies are about a quarter of the size, and approximately one tenth of the weight, of a typical human antibody.

Antibody 105

Antibody Protein Bacteria In-Vitro 105

XTalks

OCTOBER 12, 2021

14-3-3 zeta) protein, which the UToledo researchers had been studying for its role in immune-related pathologies, such as aortic aneurysms and in signaling pathways involving the pro-inflammatory cytokine interleukin-17. However, they found the opposite to be true, where the protein was actually protective against development of the disease.

Vaccination 105

Vaccination Vaccine Research Immune Response 105

Pharmaceutical Technology

MARCH 1, 2023

The drug candidate targets DNA-dependent protein kinase (DNA-PK). Merck KG, is a science and technology company. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. It is a new chemical entity. Merck overview Merck, a subsidiary of E.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

The drug candidate targets DNA-dependent protein kinase (DNA-PK). Merck KG, is a science and technology company. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. It is a new chemical entity. Merck overview Merck, a subsidiary of E.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Drug Discovery World

NOVEMBER 27, 2023

By Anis H Khimani , PhD, Senior Strategy Leader, Life Sciences strategy group, Revvity, Inc. For instance, the engineering of CHO cells, widely used protein expression system, for various metabolic pathways has resulted in improved expression levels of large molecule drugs and product quality 1,2. Metab Eng 2020;57:203.

Production 59

Production Engineer Gene Editing Gene 59

XTalks

DECEMBER 12, 2023

Plasma medicine is a critical and specialized field within healthcare, centering on the use of human plasma for the development and administration of life-saving treatments. Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

XTalks

JUNE 8, 2022

Amgen’s Riabni, a CD20-directed cytolytic antibody and biosimilar to Rituxan, got approval from the FDA on Monday for adults with moderate to severe rheumatoid arthritis. B-cell targeted therapy with the monoclonal antibody Rituxan (rituximab) is used to treat RA. million Americans. Evidence for the Efficacy of Riabni.

FDA Approval 96

FDA Approval Antibody Clinical Trials Clinical Trials 96

Drug Discovery World

MAY 5, 2023

In this webinar, you will hear from immunologist Dr Frédéric Triebel, CSO and CMO of Immutep, two experts from DeciBio: Dr Carl Schoellhammer, Principal, and Dr Joe Daccache, Senior Life Science Expert, Veronique Baron, Scientific Applications Manager, Marketing at BPS Bioscience, and Dr Hengshuo Liu, Technical Sales Specialist at ACROBiosystems.

Protein 52

Protein Life Science Sales Production 52

Drug Discovery World

APRIL 28, 2023

In this webinar, you will hear from immunologist Dr Frédéric Triebel, CSO and CMO of Immutep, two experts from DeciBio: Dr Carl Schoellhammer, Principal, and Dr Joe Daccache, Senior Life Science Expert, Veronique Baron, Scientific Applications Manager, Marketing at BPS Bioscience, and Dr Hengshuo Liu, Technical Sales Specialist at ACROBiosystems.

Protein 52

Protein Life Science Sales Production 52

XTalks

AUGUST 14, 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that its bispecific antibody Talvey (talquetamab-tgvs) received US Food and Drug Administration (FDA) approval as a fifth-line treatment for adult patients with heavily pretreated multiple myeloma. Results were similar at the higher 0.8 mg/kg dose with an ORR of 73.6

FDA Approval 97

FDA Approval Antibody Immune Response Drugs 97

XTalks

JULY 10, 2023

Rystiggo received FDA approval under the Priority Review designation, specifically for the treatment of gMG in adult patients who have tested positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. The active ingredient in Rystiggo is rozanolixizumab, a humanized IgG4 monoclonal antibody.

FDA Approval 98

FDA Approval Antibody Protein Engineer 98

Drug Discovery World

DECEMBER 14, 2023

The new hub will become a part of the already thriving life sciences sector in the Glasgow area, most of which is centred around the university, the Cancer Research UK Scotland Institute and the BioCity cluster, making Glasgow and its surrounds one of the most important regions for drug discovery and development in the UK.

Drugs 75

Drugs Life Science Research Scientist 75

Drug Discovery World

FEBRUARY 5, 2024

The launches include an integrated solution suite for liquid biopsy workflows, and the Resolvex i300 and antibody purification columns AffinEx Protein A Capture, adding biomarker discovery, drug development and personalised medicine research to proteomics workflows.

Gene Therapy 64

Gene Therapy Life Science Production Dermatology 64

Pharmaceutical Technology

MAY 8, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Antibody 147

Antibody Vaccination Vaccine Dermatology 147

XTalks

FEBRUARY 20, 2024

IgA nephropathy is an autoimmune condition characterized by the deposition of clusters of antibodies in the kidneys, resulting in inflammation and kidney impairment. These clusters, primarily comprised of IgA and other antibodies, harm the glomeruli, which are small blood vessels responsible for filtering blood in the kidneys.

Clinical Trials 59

Clinical Trials Clinical Trials FDA Approval Trials 59

pharmaphorum

JULY 20, 2021

The vaccine – now dubbed Vidprevtyn – is based on a recombinant protein antigen developed by Sanofi’s vaccines unit Sanofi Pasteur, and also includes an immune-boosting adjuvant developed by GSK that aims to boost its efficacy. 1.351) variant first identified in South Africa.

Vaccination 98

Vaccination Vaccine Protein Immune Response 98

XTalks

FEBRUARY 22, 2024

Pending full approval, datopotamab deruxtecan, developed by both companies, could mark a significant milestone as the first TROP2-directed antibody-drug conjugate (ADC) for patients with non-small cell lung cancer (NSCLC). TROP2 is a protein that is widely present in most tumors associated with NSCLC. “We

Antibody 59

Antibody Clinical Trials Clinical Trials Trials 59

XTalks

JULY 17, 2023

targeted monoclonal antibody is being evaluated for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma whose tumors are CLDN18.2-positive. This investigational first-in-class Claudin 18.2 Zolbetuximab functions by binding to the CLDN18.2

Clinical Trials 95

Clinical Trials Clinical Trials Trials Antibody 95

Drug Discovery World

MAY 11, 2023

Fundraising and investment are a core pillar of not just BioTrinity events but of the drug discovery industry at large, so events such as Tuesday’s keynote, Investment Trends for the Life Sciences Industry, are critical for members of the industry.

Life Science 52

Life Science Genetics Vaccination Vaccine 52

XTalks

JANUARY 26, 2023

Tyrosine Kinase Inhibitors for Cancer Treatment Tyrosine kinases, or TKs, are a group of signaling molecules that affect multiple downstream proteins. As with many cancers, CLL and SLL are more difficult to treat in the relapse/refractory setting.

FDA Approval 97

FDA Approval Life Science Clinical Trials Clinical Trials 97

XTalks

MARCH 28, 2024

Furthermore, the introduction of multi-targeted kinase inhibitors and monoclonal antibodies is also being examined as a possible form of therapy. Building Cancer Awareness and Empowering Métis Youth: Featuring Jordyn Playne, President, Métis Nation of Ontario Youth Council – Xtalks Life Science Podcast Ep.

Gene Editing 59

Gene Editing Life Science Clinical Trials Clinical Trials 59

Drug Discovery World

OCTOBER 16, 2023

Alchemab, on the other hand, has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires, drawing from the expertise in Cambridge to progress the company’s mission to build a broad pipeline of protective therapeutics for hard-to-treat diseases.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

XTalks

APRIL 7, 2021

As the COVID-19 pandemic shifts with new case surges largely owing to new variants of SARS-CoV-2, the US Food and Drug Administration (FDA) continues to offer up emergency use authorizations (EUA) for tests for the detection of COVID-19 infection, with the latest being antibody and antigen tests from Symbiotic and Quidel, respectively.

Antibody 102

Antibody Immune Response Radiology Marketing 102

XTalks

JUNE 28, 2023

DMD is caused by the absence of dystrophin, a protein that helps maintain the integrity of muscle cells. Elevidys’ approval was based on data from a randomized trial that showed the therapy increased expression of the Elevidys micro-dystrophin protein, which was used as a surrogate endpoint, in DMD patients aged four to five years of age.

Gene Therapy 98

Gene Therapy Gene Protein FDA Approval 98